Korro Bio, Inc.
Develops precision genetic medicines that utilize the body's natural RNA editing process.
KRRO | US
Overview
Corporate Details
- ISIN(s):
- US35803L1089 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 60 FIRST STREET, 2141 CAMBRIDGE
- Website:
- https://www.korrobio.com/
- Sector:
- Manufacturing
Description
Korro Bio, Inc. is a biopharmaceutical company focused on the discovery and development of a new class of precision genetic medicines that utilize RNA editing. The company's proprietary platform, OPERA (Oligonucleotide Promoted Editing of RNA), employs chemically modified oligonucleotides to redirect the body's naturally occurring ADAR (Adenosine Deaminase Acting on RNA) editing process. This approach enables the precise, single-base editing of RNA to repair proteins affected by genetic mutations or to modulate biological pathways. Korro Bio is advancing a pipeline of drug candidates to address a broad range of rare and prevalent diseases, with an initial program targeting Alpha-1 Antitrypsin Deficiency (AATD).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Korro Bio, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Korro Bio, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Korro Bio, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
